Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622

@article{Schott2016PhaseIS,
  title={Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622},
  author={Anne F. Schott and William Eric Barlow and Catherine H. Van Poznak and Daniel F. Hayes and Carol Moinpour and Danika L. Lew and Philip A. Dy and Evan Keller and Jill M. Keller and Gabriel N Hortobagyi},
  journal={Breast Cancer Research and Treatment},
  year={2016},
  volume={159},
  pages={87-95}
}
Bone metastases from breast cancer are common, causing significant morbidity. Preclinical data of dasatinib, an oral small molecule inhibitor of multiple oncogenic tyrosine kinases, suggested efficacy in tumor control and palliation of bone metastases in metastatic breast cancer (MBC). This clinical trial aimed to determine whether treatment with either of 2 dose schedules of dasatinib results in a progression-free survival (PFS) >50 % at 24 weeks in bone metastasis predominant MBC, to evaluate… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 33 references

The measurement of pain from metastatic bone disease: capturing the patient's experience.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2006
View 4 Excerpts
Highly Influenced

Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2002
View 7 Excerpts
Highly Influenced

TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2016
View 1 Excerpt

Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American society of clinical oncology clinical practice guideline

C Van Poznak, MR Somerfield, +12 authors LN Harris
J Clin Oncol 33:2695–2704 • 2015
View 1 Excerpt

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2014
View 7 Excerpts

Similar Papers

Loading similar papers…